Patisiran was approved by FDA recently for: (A) Filariasis, (B) Peripheral Neuropathy, (C) Neuropathy of diabetes, (D) Neuropathy of amyloidosis
Answer is D. It is a double stranded small interfering ribose neuclic acid ( si RNA) formulated in the form of a lipid complex. used in the treatment of polyneuropathy